Abstract:Despite the progress in endocrine therapy, targeted therapy and immunotherapy, the treatment of triple-negative breast cancer (TNBC), one of the most aggressive types of breast cancer, is challenging. This is closely associated with the lack of effective molecular targets in TNBC cells for therapeutic intervention. Here we report that the long noncoding RNA (lncRNA) MILIP drives TNBC cell survival, proliferation and tumorigenicity through complexing with transfer RNAs (tRNAs) to promote protein production, and thus represents a potential therapeutic target in TNBC. MILIP was expressed at high levels in TNBC cells that commonly harbor loss-of-function mutations of the tumor suppressor p53, yet MILIP silencing diminished TNBC cell viability and retarded TNBC xenograft growth, indicating that MILIP functions distinctively in TNBC beyond its well-established role in repressing p53 in other types of cancers. Mechanistical investigations revealed that MILIP interacted with eukaryotic translation elongation factor 1 alpha 1 (eEF1α1) and formed an RNA-RNA duplex with tRNALeu and tRNASer, type II tRNAs, through their variable loops, thus facilitating the binding of eEF1α1 to these tRNAs. Disrupting the interaction between MILIP and eEF1α1 or tRNAs diminished protein production and cell viability, with therapeutic potential revealed where targeting MILIP using Gapmers inhibited TNBC growth and cooperated with the clinically available protein synthesis inhibitor omacetaxine mepesuccinate in vivo. Collectively, these results identified MILIP as an RNA translation elongation factor to promote protein production in TNBC cells and demonstrated that experimental therapy with MILIP Gapmers inhibits TNBC growth, indicating MILIP targeting is a potential avenue for developing improved TNBC treatment through blocking protein synthesis. Citation Format: Yuchen Feng, Simin Zheng, Xiaohong Zhao, Yuanyuan Zhang, Ran Xu, Liang Xu, Thomas Preiss, Lei Jin, Jinnan Gao, Xu Dong Zhang. MILIP drives triple-negative breast cancer through complexing with transfer RNAs to promote protein production [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5697.

Supplementary Fig. S2. from MILIP Binding to Trnas Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S1. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S7. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S5. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S3. from MILIP Binding to Trnas Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S4. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

MILIP Binding to Trnas Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Fig. S6. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Table S7. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Table S8. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Abstract 5697: MILIP drives triple-negative breast cancer through complexing with transfer RNAs to promote protein production

Supplementary Table S6. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Table S1. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

Supplementary Table S4. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple‐negative breast cancer

Supplementary Table S5. from MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer

The pan-cancer lncRNA MILIP links c-Myc to p53 repression

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.

Micropeptide CIP 2A‐ BP Encoded by LINC 00665 Inhibits Triple‐negative Breast Cancer Progression

c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis